Solr Search

alled tau—a common culprit in a number of neurodegenerative diseases—we make the case that focused strategic investment in tau research and the , At present, no disease-modifying therapies for the pure tauopathies exist. Researchers are working to develop effective therapeutic agents, which include approaches such as decreasing the amount of tau within the brain., Symptomatic Interventions At present, no disease-modifying therapies for the pure tauopathies exist.

ct philanthropists are poised to lead that effort like never before.    

re biomedical research ecosystem at risk.

inancial and public crises as they work to mitigate immediate needs—and the age of COVID-19 has been no different.

rain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe.

h challenges for people on college campuses, and created new ones as online learning expands, key rites of passage are cancelled, and social isolation con

s of people requiring care.

hem requires constant innovation and the expertise of multiple fields of study.  

ort Alliance collaborated to develop a first of its kind community survey.

stant. The most catastrophic forms of epilepsy occur in very young children and have a lifelong negative impact on patients, families, an